Τόμος 26 (2008) – Τεύχος 2 – Άρθρο 8 – Επιθεώρηση Κλινικής Φαρμακολογίας και Φαρμακοκινητικής-Ελληνική Έκδοση – Volume 26 (2008) – Issue 2– Article 8 – Epitheorese Klinikes Farmakologias και Farmakokinetikes-Greek Edition

Παναγιώτης Κ. Μάλλιος, Κωνσταντίνος Δ. Μάλλιος

Α΄ Καρδιολογική Κλινική Θεραπευτηρίου Αθηνών Υγεία, Λ. Κηφισίας και Ερ. Σταυρού 4, 15123 Μαρούσι, Αθήνα, Ελλάς

Panagiotis C. Mallios, Constantine D. Mallios

A΄ Cardiac Department Diagnostic and Therapeutic Center Hygeia. Av. Kifissias and Er. Stavrou 4, 15123 Maroussi, Athens Creece

2. Tang Y.D., Katz S.D.: Anemia in chronic heart failure: prevalence, etiology, clinical correlates, and treatment options. Circulation 113: 2454-2461 (2006)

3. Michaell J.: Emerging role of anemia in heart failure. Am. J. Cardiol. 66: 150-200 (2007)

4. Silverberg D.S., Wexlar D., Iaina A.: The importance of anemia and its correction in the management of severe congestive heart failure. Eur. J. Heart Fail. 4: 681-686 (2002)

5. Taner H., Moschovitis G., Kusha G.M., et al.: The prevalence of anemia in chronic heart failure. Inter. J. Cardiol. 81: 115-121 (2002)

6. Anand I., McMurray U., Whimore J., et al.: Anemia and its relatiohip to clinica outome in heart failure. Circulation 110: 149-154 (2003)

7. Maggioni A.P., Opasich C., Anand I., et al.: Anemia in patients with heart failure: prevalence and prognostic, tole in a cotrollod trial and in clinical practice. J. Card. Fail. 11: 91-98 (2005)

8. Kamajda M.: Prevalence of anemia in patients with heart failure and their clinical characteristics. J. Card. Fail. 10: 51-54 (2004)

9. V. NKF K/DOQI: Clinical practice guidilines for anemia of chronic kindey disease uptate 2000. Am. J. Kindey Dis. 37: S182-S238 (2001)

10. Horwich T.B., Fonarow G.C., Hamilton M.A., et al.: Anemia in associated with worse symptoms, greater impairmant in functional capacity and a significant icrease in mortality in patients with advanced heart failure. JACC 39: 1780-1786 (2002)

11. Ezekovitz J.A., McAlister F.A., Armstrong R.W.: Anemia in common in heart fallure and is associated with poor outcomes insights from a cohory of 12.065 patients with novo-onset heart failure. Circulation 107: 223-225 (2003)

12. Kasihorod M., Smith G.I., Radfand M.J.: The prognostic importance of anemia in patients with heart failure. An. J. Med. 114: 112-119 (2003)

13. Sharma R., Francis D.P., Pitt B., et al.: Haemoglobin predicts survival in patients with chronic heart failure: a substudy of the ELITE II trial. Eur. Heart J. 25: 1021-1028 (2004)

14. Wolf R.F., Gilmore L.S., Friese P., et al.: Erythtopoietin potentiales thrombus developement in a canine arteriovenous shunt model. Tromb. Haemost. 77:1020-1024 (1997)

15. Jelkmann W.: Molecular biology of erythropoietin. Intern. Med. 43: 649-659 (2004)

16. Moise K., Li F., Chang Z.Z.: New avenues of expreration for erythropoietin. JAMA 293: 90-95 (2005)

17. van de Meer P., Lipsic E., Henning R.H., et al.: Erythtropoietin indices neovascularization and improves cardiac failure in rats with heart fallure after myocardial infarction. JACC 46: 125-133 (2005)

18. Hirata A., Kommira T., Asanuma H., et al.: Erythropoietin enhances neovascularization of ischemic myocadim and improves left ventricular disfunction after myocardial infarction in dogs. JACC 48: 176-184 (2006)

19. van de Meer P., Voors A.A., Lipsic F., et al.: Prognostic value of plasma erythropoietn on mortality in patients with chronic heart failure. JACC 44: 63-67 (2004)

20. Cohen Sotal A., Beauvais F.: Anemie, insuffissance cardiaque et erythropoietine. Arch. Mal. Coeur 98: 997-1001 (2005)

21. Bolger A.P., Doehner W., Sharma R., et al.: Anemia in chronic heart faiure the relatioship to inflammatory cytokine expression and prognostic importance. Circulation 106 (Suppl.): 570-571 (2002)

22. Macdougall I.C., Cooper A.C.: Erythropoietin resistance: the value of inflammation and pro-inflammatory cytokines. Nephrol. Dial. Transplant. 17(Suppl.II): 30-43 (2002)

23. McGlellan W.M., Flanders W.D., Langston R.D., et al.: Anemia and renal insuffisiciency are independant risk factor for death among patients with congestive heart failure admitted to community hospitals:a population-based study. J. Am. Soc. Nephrol. 13: 1928-1936 (2002)

24. Foley R.N.: Myocardial disease, anemia and erythro-cyte-stimulating proteins in chronic heart disease. Rev. Cardiovascul. Med. 6 (Suppl. 3): S27-S34 (2005)

25. McCullough P.A., Lepor N.E.: Piecing together the evidence on anemia: the link between chronic kidney disease and cardiovascular disease. Rev. Cardiovasc. Med. 6(Suppl. 3): S4-S12 (2005)

26. Androne A.S., Katz S.D., Lund F., et al.:. Hemodilution is common in patients with advanced heart failure. Circulation 107: 226-229 (2003)

27. Westenbrink B.D., Visser F.W., Voors A.A., et al.: Anaemia in chronic failure is not only related to impaired renal and blunted erythropoietin production, but to fluid retention as well. Wur. Heart J. 28: 166-171 (2007)

28. Weis G., Goodnough L.T.: Anemia in chronic disease. N. Engl. J. Med. 353: 1041-1063 (2005)

29. Katz S.D.: Mechanims and treatment of anemia in chronic heart failure. Congest. Heart Fail. 10: 243-247 (2004)

30. Ishani A., Weinhandl E., Zhao Z., et al.: Angiotensinconverting enzyme inhibitor as risk factor for the development of anemia and the impact of incident anemia on mortality in patients with left ventricular dysfunction. JACC 45: 391-399 (2005)

31. van der Meer P., Lipsic E., Westenbrink B.D., et al.: Levels of hematopoiesis inhibitor: N-acetyl-seryl-aspertyl-lysyl-proline partially explain the occurrence of anemia in heart failure. Circulation 112: 1743-1747 (2005)

32. Anand I.S.: Pathogenesis of anemia in cardiorenal disease. Rev. Cardiovasc. Med. 6 (Suppl.31): S13-S21 (2005)

33. Mancini D.M., Katz S.D., Lang C.C., et al.: Effect of erythropoietin on exercise capacity in patients with moderate to severe chronic heart failure. Circulation 107: 294-299 (2003)

34. Bolger A., Bartlett F.R., Postou H.S., et al.: Intravenus iron alone for the treatment of anemia in patients with chronic heart failure. JACC 48: 1225-1227 (2006)

35. Cleland I.G., Solliva J.T., Bell S., et al.: Once-monthly administration of darbepoetin alpha for the treatment of patientw with chronic heart failureand anemia. A Pharmacokinetic and pharmacodynamic investigation. J. Cardiovasc. Pharmacol. 46: 151-161 (2005)

36. Ponikowski P., Anter S.D., Szachniewicz J., et al.: Effects of darbepoetin alpha on exercise tolerance in anemic patients with symptomatic chronic heart failure. JACC 49: 753-762 (2007)

37. Kourea K., Parissis J., et al.: Recombinant human erythropoietin improves in vascullar diastolic and systolic function, and reduces plasma biomakers of neurohormonal activationin patiens with chronic heart failure and anemia. AHA poster competition award (11/ 2006)

38. van de Meer P., Voors A.A., Lipsic F., et al.: Erythropoietin in cardiovascular disease. Eur. Heart J. 25: 285-291 (2004)